Last reviewed · How we verify
POMA
Poma is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect.
Poma is a small molecule drug developed by the New York State Psychiatric Institute, currently owned by Bristol. However, due to the lack of available information, its target, drug class, and approved indications are unknown. Poma is available as a generic medication, with six generic manufacturers, but its commercial status as patented or off-patent is unclear. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to fully understand Poma's characteristics and clinical applications.
At a glance
| Generic name | POMA |
|---|---|
| Also known as | Pomaglumetad |
| Sponsor | Bristol |
| Target | Protein cereblon, Cereblon isoform 4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Imagine Poma as a key that fits into a lock in our cells. When it binds to the lock, it triggers a series of events that help to treat a particular condition. This process is complex and involves many different molecules and cellular pathways.
Approved indications
- Multiple myeloma
Common side effects
- Dose interruption due to adverse reactions
- Dose reduction due to adverse reactions
Serious adverse events
- Discontinuation due to adverse reactions
- Serious adverse reactions (KS patients)
- Myocardial infarction
- Atrial fibrillation
- Cardiac failure congestive
- Pulmonary embolism
- Respiratory failure
- Septic shock
- Neutropenic sepsis
- Interstitial lung disease
Key clinical trials
- Evaluation Of The Relationship Between The Conut Score And Balance And Functional Status In Patients With Chronic Stroke
- Relation of Functional ındependence to Balance, Exercise Capacity, and Peripheral Muscle Strength
- Translation and Validation of the Performance Oriented Mobility Assessment (Poma) Scale Into Urdu Version
- Urdu Version of Tinetti Balance and Gait Assessment Scale,(POMA),Reliability and Validity Study
- Glutamate Reducing Interventions in Schizophrenia (PHASE1)
- Effects of Compelled Body Weight Shift Technique for Rehabilitation of Individuals With Chronic Stroke (NA)
- Pomaglumetad Effects on Glutamate Biomarkers (PHASE1)
- Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma (PHASE1,PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- POMA CI brief — competitive landscape report
- POMA updates RSS · CI watch RSS
- Bristol portfolio CI